Nanosuspensions in drug delivery

A surprisingly large proportion of new drug candidates emerging from drug discovery programmes are water insoluble, and therefore poorly bioavailable, leading to abandoned development efforts. These so-called 'brickdust' candidates can now be rescued by formulating them into crystalline nanosuspensions. In the process of overcoming issues involving solubility, additional pharmacokinetic benefits of the drugs so formulated have come to be appreciated. As such, insolubility issues of the past have provoked a paradigm change, which now offers novel solutions for innovative drugs of the future.

[1]  Gordon L. Amidon,et al.  Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size , 1996, Pharmaceutical Research.

[2]  I. Gonda,et al.  Development of a systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulized in polydisperse droplets , 1988 .

[3]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[4]  G. Wolf,et al.  Time course of nodal enhancement with CT X-ray nanoparticle contrast agents: effect of particle size and chemical structure. , 2000, Investigative Radiology.

[5]  A. Myerson.  Handbook of Industrial Crystallization , 2002 .

[6]  J. Kreuter.  Peroral administration of nanoparticles , 1991 .

[7]  T. Barber.  Pharmaceutical Particulate Matter: Analysis and Control , 1993 .

[8]  Mark L. Greenberg,et al.  Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Müller,et al.  Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. , 2000, International journal of pharmaceutics.

[10]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[11]  N. Joseph,et al.  Effect of Epidural and Subarachnoid Injections of a 10% Butamben Suspension , 1990, Regional Anesthesia & Pain Medicine.

[12]  R. Robison,et al.  Formulation design and development of parenteral suspensions. , 1987, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[13]  Martin Kuentz,et al.  Rapid assessment of sedimentation stability in dispersions using near infrared transmission measurements during centrifugation and oscillatory rheology. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  S. Waldman,et al.  The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[15]  S. Grossman,et al.  Leptomeningeal carcinomatosis. , 1999, Cancer treatment reviews.

[16]  V. Stella,et al.  Lymphatic Transport of Drugs , 1992 .

[17]  A. Poklis.  A Review of Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs , 1987 .

[18]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[19]  J. Rieger,et al.  Organic Nanoparticles in the Aqueous Phase-Theory, Experiment, and Use. , 2001, Angewandte Chemie.

[20]  W. D. Pandolf.  High-pressure homogenization , 2019, World Pumps.

[21]  M. Kaufman,et al.  Characterization of Crystalline Drug Nanoparticles Using Atomic Force Microscopy and Complementary Techniques , 2003, Pharmaceutical Research.

[22]  Alvin Lieberman,et al.  Liquid- and surface-borne particle measurement handbook , 1996 .

[23]  W. Seeger,et al.  Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Claus-Michael Lehr,et al.  Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa , 2001, Pharmaceutical Research.

[25]  C. Nyström,et al.  The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. , 1999, International journal of pharmaceutics.

[26]  P. York,et al.  Entropy of processing: a new quantity for comparing the solid state disorder of pharmaceutical materials , 1986 .

[27]  R. McLendon,et al.  Intrathecal Busulfan Treatment of Human Neoplastic Meningitis in Athymic Nude Rats , 2004, Journal of Neuro-Oncology.

[28]  S. Gad.  Drug Safety Evaluation , 2002 .

[29]  I. Fichtner,et al.  Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models , 2001, Pharmaceutical Research.

[30]  K. Yoshii.  Application of Differential Scanning Calorimetry to the Estimation of Drug Purity : Various Problems and Their Solutions in Purity Analysis , 1997 .

[31]  Helmut Hahn,et al.  Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis , 2001, Antimicrobial Agents and Chemotherapy.

[32]  G. Liversidge,et al.  Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .

[33]  K. Audus,et al.  Microparticulate uptake mechanisms of in‐vitro cell culture models of the respiratory epithelium , 2001, The Journal of pharmacy and pharmacology.

[34]  S. Yalkowsky,et al.  Studies in phlebitis. VI: Dilution-induced precipitation of amiodarone HCL. , 1993, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[35]  K. Mohr.  High-pressure homogenization. Part I. Liquid-liquid dispersion in turbulence fields of high energy density , 1987 .

[36]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[37]  A. Joshi.  Microparticulates for ophthalmic drug delivery. , 1994, Journal of ocular pharmacology.

[38]  N. Kelekis,et al.  High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours , 2000, British Journal of Cancer.

[39]  M. Gallarate,et al.  Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. , 2003, International journal of pharmaceutics.

[40]  J. Dressman,et al.  In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  H. Bosch,et al.  Sterile Filtration of NanoCrystal™ Drug Formulations , 1997 .

[42]  Christos Reppas,et al.  Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration , 2001, Pharmaceutical Research.

[43]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  L. Perlemuter.  [From theory to practice]. , 1997, Soins. Psychiatrie.

[45]  S. Howard,et al.  Dissolution performance related to particle size distribution for cohpiercially available prednisolone acetate suspensions , 1992 .

[46]  L. Willems,et al.  Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics , 2001, Journal of clinical pharmacy and therapeutics.

[47]  Dominique Duchêne,et al.  Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract , 1997 .

[48]  H. Toguchi.  Sterility assurance of microspheres. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[49]  A. Florence,et al.  Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency , 1990, The Journal of pharmacy and pharmacology.

[50]  Beate Bittner,et al.  Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.

[51]  Maria José Alonso,et al.  Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport , 2002, Pharmaceutical Research.

[52]  D. Grant,et al.  The use of thermal analysis in the assessment of crystal disruption , 1995 .

[53]  Robert Gurny,et al.  Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. , 2002, International journal of pharmaceutics.

[54]  R. Müller,et al.  Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. , 2000, International journal of pharmaceutics.

[55]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[56]  W. D. Pandolfe.  EFFECT OF DISPERSED AND CONTINUOUS PHASE VISCOSITY ON DROPLET SIZE OF EMULSIONS GENERATED BY HOMOGENIZATION , 1981 .

[57]  W. D. Pandolfe.  Development of the New Gaulin Micro-Gap™ Homogenizing Valve , 1982 .

[58]  R. Liu.  Water-insoluble drug formulation , 2000 .

[59]  Huibi Xu,et al.  Oleanolic acid nanosuspensions: preparation, in‐vitro characterization and enhanced hepatoprotective effect , 2005, The Journal of pharmacy and pharmacology.

[60]  R. Müller,et al.  Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration , 2002, Pharmaceutical Research.

[61]  S. Yalkowsky.  Techniques of solubilization of drugs , 1981 .

[62]  H. Bosch,et al.  An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[63]  B H Boedeker,et al.  Ultra‐Long‐Duration Local Anesthesia Produced by Injection of Lecithin‐Coated Tetracaine Microcrystals , 1994, Journal of clinical pharmacology.

[64]  P. Sado,et al.  Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.

[65]  Gilbert S. Banker,et al.  Pharmaceutical Dosage Forms: Disperse Systems , 1988 .

[66]  Sanyog Jain,et al.  Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. , 2004, International journal of pharmaceutics.

[67]  Cesario Z. Cerna,et al.  Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry , 2002, Pharmaceutical Research.

[68]  A. Fisher.  Adverse Reactions to Drug Formulation Agents , 1990 .

[69]  P. O'dwyer,et al.  Hypersensitivity reactions induced by etoposide. , 1984, Cancer treatment reports.

[70]  G. Liversidge,et al.  The surface modified drug nanoparticles , 1992 .

[71]  K. Johnston,et al.  Enhanced drug dissolution using evaporative precipitation into aqueous solution. , 2002, International journal of pharmaceutics.

[72]  G. Russell-Jones,et al.  Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. , 1999, International journal of pharmaceutics.

[73]  G. Na,et al.  Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization , 1999, Pharmaceutical Research.

[74]  K Borner,et al.  Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. , 2000, The Journal of antimicrobial chemotherapy.

[75]  T. Martonen,et al.  Deposition Patterns of Aerosolized Drugs Within Human Lungs: Effects of Ventilatory Parameters , 1993, Pharmaceutical Research.

[76]  R. Reed,et al.  Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. , 2003, Analytical chemistry.

[77]  Bernhard A. Sabel,et al.  Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections , 1996, Brain Research.

[78]  O. Kayser,et al.  Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages. , 2000, International journal of pharmaceutics.

[79]  R. Langer,et al.  Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[80]  R. Müller,et al.  The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. , 2001, International journal of pharmaceutics.

[81]  D. Giron.  Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates , 1995 .

[82]  R. Bodmeier,et al.  Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method , 1988 .

[83]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[84]  R. Pignatello,et al.  Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[85]  R. W. Wood,et al.  Nebulization of NanoCrystals™: Production of a Respirable Solid-in-Liquid-in-Air Colloidal Dispersion , 2004, Pharmaceutical Research.

[86]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[87]  B. Hirst,et al.  Exploiting M cells for drug and vaccine delivery. , 2001, Advanced drug delivery reviews.

[88]  S. Davis,et al.  Lipid Emulsions as Drug Delivery Systems , 1987, Annals of the New York Academy of Sciences.

[89]  Weiss Rb,et al.  Hypersensitivity reactions induced by etoposide. , 1984 .

[90]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[91]  P. Gassmann,et al.  Hydrosols : alternatives for the parenteral application of poorly water soluble drugs , 1994 .

[92]  G. Duchateau,et al.  Release and absorption rate aspects of intramuscularly injected pharmaceuticals , 1988 .

[93]  C Olbrich,et al.  Formulation of amphotericin B as nanosuspension for oral administration. , 2003, International journal of pharmaceutics.

[94]  D. Andes.  In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.

[95]  J. M. Shaw,et al.  Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.

[96]  H. Viernstein,et al.  Similar central actions of intravenous methohexitone suspension and solution in the rabbit , 1992, The Journal of pharmacy and pharmacology.

[97]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[98]  D A Weitz,et al.  Trojan particles: Large porous carriers of nanoparticles for drug delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[99]  I. Uchegbu.  Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, Edited by R.H. Muller, S. Benita, B. Bohm, Medpharm Scientific Publishers, Stuttgart, 1998. ISBN 3-88763-069-6 , 2001 .

[100]  Dominique Duchêne,et al.  Bioadhesion of solid oral dosage forms, why and how? , 1997 .

[101]  Raviraj M. Kulkarni,et al.  Nanosuspensions: a promising drug delivery strategy , 2004, The Journal of pharmacy and pharmacology.

[102]  S. Muldoon,et al.  Intravenous Lecithin-Coated Microcrystals of Dantrolene Are Effective in the Treatment of Malignant Hyperthermia: An Investigation in Rats, Dogs, and Swine , 1996, Anesthesia and analgesia.

[103]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[104]  R. Müller,et al.  Influence of high pressure homogenisation equipment on nanodispersions characteristics. , 2000, International journal of pharmaceutics.

[105]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[106]  A. Dwivedi,et al.  Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis , 2001, Pharmaceutical Research.

[107]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.